Current stock page

Stock Analysis

Summit Therapeutics Inc. (SMMT) Stock Analysis

Summit Therapeutics Inc. (SMMT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

SMMT Stock Analysis Summary

Summit Therapeutics Inc. (SMMT) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 65/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

SMMT at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$14.15
AIQ Score47/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$11.29B
P/E Ratio (TTM)-13.22
Forward P/E—
EPS (Q3 FY2026)-$0.26
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.89
Volume5.56M
52-week range$12.07-$29.23
RSI 1442.17
50-Day SMA$16.41
200-Day SMA$16.15
Analyst Price Target$31.50
Next EarningsFeb 22, 2027
As of Nov 13, 2026 · Market close

SMMTSummit Therapeutics Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$14.15−$0.92 (−6.14%)

Latest quote

  • Momentum
    65
  • Value
    —
  • Quality
    30
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

SMMT Stock Analysis Summary

Summit Therapeutics Inc. (SMMT) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 65/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, SMMT has AIQ Score of 47/100 with Momentum base of 65/100 and fading Quality at 30/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (65/100) leads while Quality (30/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -6.14% stock move · SMMT classified in Biotechnology.

Current Evidence

BearishSMMT is in a bearish AIQ regime; Momentum is the strongest visible factor at 65/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is SMMT Bullish or Bearish Right Now?

SMMT currently has a bearish overall setup. Momentum is the strongest factor at 65/100, while Quality is weakest at 30/100. The current evidence suggests a bearish setup.

Bull Case
  • - Momentum is constructive at 65/100.
  • - Analyst target implies +122.61% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 38/100.
  • - Price is -12.37% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (35 vs 7).

Current Consensus

SMMT's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 4 neutral, and 35 sell votes. SMMT's 14-day RSI is 42.17, which places the stock in a weaker momentum range. SMMT's beta is 1.89, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in SMMT?

The largest recent change in SMMT is Momentum moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+3.0
Quality
+1.0
Risk
-1.0

What Would Change the SMMT Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

SMMT Decision Framework

Public evidence layers, setup checks, and risk context for Summit Therapeutics Inc..

Summit Therapeutics Inc. (SMMT) Stock Analysis

Summit Therapeutics Inc. has an AIQ Score of 47/100 in a Bearish regime. Momentum is strongest at 65/100. Beta is 1.89, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextSMMT is in a Bearish AIQ regime with score 47/100.
Signal ConflictThe primary conflict is that momentum leads at 65/100 while quality lags at 30/100.
Factor EvidenceMomentum 65/100 · Quality 30/100 · Risk 38/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 65/100.

TimingPass

Momentum is 65/100 and RSI (14) is 42.2.

Regime fitFail

SMMT is in a Bearish regime at 47/100.

Risk controlFail

Risk factor is 38/100 with beta 1.89 and annual volatility 75.92%.

ConflictWait

Current conflict: momentum leads at 65/100 while quality lags at 30/100.

AIQ Score
47/100
Price
$14.15
Beta
1.89
RSI (14)
42.2

SMMT Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

SMMT Fundamentals

SMMT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$208.39M
Free cash flow
-$160.21M
View full SMMT fundamental analysis

SMMT Technical Analysis

SMMT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
42.17
Price vs SMA-50
-13.78%
View full SMMT technical analysis

SMMT Stock Catalysts

Track SMMT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 22, 2027
Analyst target
$31.50
News items
5
View SMMT earnings and stock catalysts

SMMT Dividend Analysis

SMMT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View SMMT dividend history and analysis

SMMT Financial Data

SMMT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.26
Periods
8
View SMMT financials

SMMT Risk Analysis

SMMT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.89
Risk score
38/100
1Y volatility
75.92%
View SMMT risk analysis

SMMT Stock News

SMMT stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read SMMT stock news

SMMT vs Biotechnology Peers

Current peer cohort: SMMT · SNDX · SRRK · STOK · SYRE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
SMMT
Current stock
47/100—65/10038/100-0.0175.92%Current
SNDX
Syndax Pharmaceuticals, Inc.
43/10064/10014/10037/100-0.7657.16%SMMT vs SNDX
SRRK
Scholar Rock Holding Corporation
39/100—54/10052/1000.8457.45%SMMT vs SRRK
STOK
Stoke Therapeutics, Inc.
42/10022/10047/10059/1000.2353.19%SMMT vs STOK
SYRE
Spyre Therapeutics, Inc.
64/10044/10081/10053/1002.5766.66%SMMT vs SYRE
Pairwise Compare links: SNDX · SRRK · STOK · SYRESMMT vs SNDXSMMT vs SRRKSMMT vs STOKSMMT vs SYRECompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a SMMT stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for SMMT: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-13.22
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.04
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$208.39M
Quarter free cash flow
-$160.21M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
42.17
MACD
-0.09

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
38/100
Beta
1.89
Annual volatility
75.92%
Max drawdown
-52.88%

SMMT Stock FAQ

What is SMMT stock price today?

Summit Therapeutics Inc.'s current stock price is $14.15. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is SMMT bullish or bearish right now?

SMMT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is SMMT's market cap?

SMMT's market cap is $11.29B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is SMMT's current P/E ratio?

SMMT's current P/E ratio is -13.22 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is SMMT's RSI?

SMMT's 14-day RSI is 42.17 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is SMMT above its 50-day and 200-day moving averages?

SMMT is -13.78% from its 50-day SMA and -12.37% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is SMMT's next earnings date?

SMMT's next earnings date is currently listed as Feb 22, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does SMMT pay a dividend?

SMMT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.